Mosquito-borne illnesses in travelers: A review of risk and prevention

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 1031-1043

  Mirzaian, Edith ^a   Durham, Melissa J ^a   Hess, Karl ^b   Goad, Jeffery A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Chikungunya fever; Dengue fever; Japanese encephalitis; Malaria; Mosquito bite prevention; Mosquito borne illness; Travel consultation; West Nile virus; Yellow fever

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DENGUE VACCINE; DOXYCYCLINE; IC 51; INACTIVATED VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; MEFLOQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRIMAQUINE; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

AEDES; AFRICA; ANGIONEUROTIC EDEMA; ANOPHELES; ASIA; BELL PALSY; BLEEDING; BRONCHOSPASM; BULBAR PARALYSIS; CARDIOTOXICITY; CENTRAL AMERICA; CHEMOPROPHYLAXIS; CHIKUNGUNYA ALPHAVIRUS; CULEX; DENGUE; DISEASE TRANSMISSION; ENCEPHALOMYELITIS; EPIDEMIC ENCEPHALITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MALARIA; MENINGOENCEPHALITIS; MENTAL DISEASE; MIDDLE EAST; MORBIDITY; MORTALITY; MOSQUITO; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NURSE; PACIFIC ISLANDS; PHARMACIST; PHOTOSENSITIVITY; PHYSICIAN; PRURITUS; REVIEW; REYE SYNDROME; SEIZURE; SOUTH AMERICA; TRAVEL; UNITED STATES; URTICARIA; VAGINA CANDIDIASIS; VISUAL IMPAIRMENT; VOMITING; WEST NILE FLAVIVIRUS; YELLOW FEVER;

ANIMALS; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; CULICIDAE; DEVELOPING COUNTRIES; DISEASE VECTORS; HUMANS; POPULATION SURVEILLANCE; RISK; TRAVEL; VACCINES;

EID: 77957689541     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.1031     Document Type: Review

References (68)

1. ITA Office of Travel and Tourism Industries. Monthly U.S. outbound air travel to international regions. Available from http://www.tinet.ita.doc.gov/ view/m-2008-O-001/index.html. Accessed December 27, 2009.
2. Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med 2005;142:67-72.
3. Centers for Disease Control and Prevention. CDC health information for international travel 2010. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, 2009.
4. World Health Organization. International travel and health 2009. Available from http://www.who.int/ith/ITH2009. Accessed December 29, 2009.
5. Fradin MSMD. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998;128:931-40.
6. Cox-Singh J, Singh B. Knowlesi malaria: newly emergent and of public health importance? Trends Parasitol 2008;24:406-10.
7. Cox-Singh J, Davis T, Lee K, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46:165-71.
8. Mali S, Steele S, Slutsker L, Arguin PM. Malaria surveillance: United States, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1-16.
9. Newman RD, Parise ME, Barber AM, Steketee RW. Malariarelated deaths among U.S. travelers, 1963-2001. Ann Intern Med 2004;141:547-55.
10. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006;354:119-30.
11. Fairhurst R, Willems T. Plasmodium species (malaria). In: Mandell D, Bennett J, eds. Principles and practice of infectious diseases, 7th ed (electronic version). Philadelphia, PA: Elsevier, 2010.
12. Freedman DO. Clinical practice; malaria prevention in shortterm travelers. N Engl J Med 2008;359:603-12.
13. Keystone J. Reemergence of malaria: increasing risks for travelers. J Travel Med 2001;8:S42-7.
14. Gubler D. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 2006;277:3-16; discussion 22.
15. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention, and control. Geneva, Switzerland: WHO Press, 2009.
16. Tan GK, Alonso S. Pathogenesis and prevention of dengue virus infection: state-of-the-art. Curr Opin Infect Dis 2009;22:302-8.
17. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007;30:329-40. (Pubitemid 47450087)
18. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005;353:924-32.
19. Kuno G. Emergence of the severe syndrome and mortality associated with dengue and dengue-like illness: historical records (1890-1950) and their compatibility with current hypotheses on the shift of disease manifestation. Clin Microbiol Rev 2009;22:186-201.
20. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 2008;92:1377-90.
21. World Health Organization. Dengue/dengue haemorrhagic fever in Brazil, 2009. Available from http://www.who.int/csr/ don/2008-04-10/en/index.html. Accessed December 28, 2009.
22. World Health Organization. Dengue and dengue haemorrhagic fever, 2009. Available from http://www.who.int/mediacentre/ factsheets/fs117/en/index.html. Accessed December 28, 2009.
23. Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel surveillance network. Clin Infect Dis 2007;44:1560-8.
24. Keller TH, Chen YL, Knox JE, et al. Finding new medicines for flaviviral targets. Novartis Found Symp 2006;277:102-14.
25. Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev Vaccines 2008;7:569-78.
26. Heintze C, Garrido MV, Kroeger A. What do community-based dengue control programmes achieve? A systematic review of published evaluations. Trans R Soc Trop Med Hyg 2007;101: 317-25.
27. World Health Organization. Guidelines on clinical management of chikungunya fever, 2008. Available from http://www. searo.who.int/LinkFiles/ Publication-guidelines-on-cli-mgmt-c hikungunya-fvr-(cd-180).pdf. Accessed December 29, 2009.
28. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a reemerging infectious disease. Clin Infect Dis 2009;49:942-8.
29. World Health Organization. Chikungunya fever, a reemerging disease in Asia. 2009. Available from http://www.searo.who.int/ en/Section10/Section2246. html. Accessed December 28, 2009.
30. de Lamballerie X, Ninove L, Charrel RN. Antiviral treatment of chikungunya virus infection. Infect Disord Drug Targets 2009;9:101-4.
31. Shoreland, Inc. West Nile virus. Available from www.travax.com. Accessed December 27, 2009.
32. Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004;140:545-53. (Pubitemid 38437027)
33. Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003;78:1137-43.
34. Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005;18:387-94.
35. World Health Organization. Initiative for vaccine research. West Nile virus. Available from http://www.who.int/vaccine- research/diseases/vector/en/ index3.html. Accessed December 27, 2009.
36. Centers for Disease Control and Prevention. 2009 West Nile virus activity in the United States: statistics, surveillance, and control. Available from http://www.cdc.gov/ncidod/dvbid/ westnile/mapsactivity/surv&control09Maps. html. Accessed December 27, 2009.
37. Chiodini J. Mosquito-borne viral infections and the traveller. Nurs Stand 2008;22:50-7.
38. Cunha BA. Differential diagnosis of West Nile encephalitis. Curr Opin Infect Dis 2004;17:413-20.
39. Shlim D, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002;35:183-8. (Pubitemid 34753904)
40. van der Hurk A, Ritchie S, Mackenzie J. Ecology and geographical expansion of Japanese encephalitis virus. Ann Rev Entomol 2009;54:17-35.
41. World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006;81:331-40.
42. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 1993;42:1-16.
43. Buhl M, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J Travel Med 2009;16:217-19.
44. Centers for Disease Control and Prevention. Provisional recommendations for the use of Japanese encephalitis vaccine. Available from http://www.cdc.gov/vaccines/recs/provisional /downloads/je-july2009-508.pdf. Accessed November 21, 2009.
45. Gambel J, DeFraites R, Hoke C, et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series [letter]. J Infect Dis 1995;171:1074.
46. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenciity of a vero-cell-derived, inactivated Japanese encephalitis vaccine: a noninferiority, phase III, randomised controlled trial. Lancet 2007;370:1847-53. (Pubitemid 350186053)
47. Berg S, Mitchell B, Hanson K, et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997;24:265-6.
48. Intercell Biomedical. Ixiaro (Japanese encephalitis vaccine, inactivated, adsorbed) package insert. Livingston, United Kingdom; 2009.
49. Duggan S, Plosker G. Japanese encephalitis vaccine (inactivated, adsorbed [Ixiaro]). Drugs 2009;69:115-22.
50. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo controlled phase III trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198:493-9.
51. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: 6- and 12-month results of a multicenter follow-up phase III study. Vaccine 2008;26:4382-6.
52. Gubler DJ. Human arbovirus infections worldwide. Ann N Y Acad Sci 2001;951:13-24.
53. Nasidi A, Monath TP, DeCock K, et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg 1989;83:401-6.
54. Sanders EJ, Tukei PM. Yellow fever: an emerging threat for Kenya and other east African countries. East Afr Med J 1996;73:10-12. (Pubitemid 26409851)
55. Centers for Disease Control and Prevention, Division of Vector Borne Infectious Diseases. Yellow fever transmission. Available from http://www.cdc.gov/ncidod/dvbid/yellowfever/ YF- Transmission.html. Accessed December 15, 2009.
56. World Health Organization. WHO-recommended surveillance standard of yellow fever. Available from http://www.who.int/ immunization-monitoring/ diseases/YF-surveillance/en/index.h tml. Accessed December 15, 2009.
57. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002;34:1369-78.
58. World Health Organization, Department of Immunization, Vaccines and Biologicals. WHO vaccine-preventable diseases: monitoring system 2008 global summary. Switzerland; 2008. Available from http://whqlibdoc.who.int/hq/2008/WHO- IVB- 2008-eng.pdf. Accessed December 22, 2009.
59. Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005;19:151-68.
60. Monath TP. Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-74.
61. Sanofi Pasteur, Inc. YF-VAX (yellow fever vaccine) package insert. Swiftwater, PA; 2008.
62. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of yellow fever vaccine. Available from http://www.cdc.gov/vaccines/recs/provisional/downloads/ yf-vac-dec-2009-508.pdf. Accessed December 15, 2009.
63. Centers for Disease Control and Prevention. ACIP yellow fever working group meeting slides. Available from http://www.cdc.gov/vaccines/recs/acip/ downloads/mtg-slidesoct09/ 09-yellow-fever.pdf. Accessed December 15, 2009.
64. World Health Organization. International health regulations 2005, 2nd ed. Switzerland; 2008. Available from http://whqlibdoc. who.int/publications/2008/ 9789241580410-eng.pdf. Accessed December 22, 2009.
65. Leder K, Black J, O'Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004;39:1104-12. (Pubitemid 40169306)
66. Rose SR, Keystone JS. International travel health guide, 13th ed. Philadelphia, PA: Mosby Elsevier, 2006.
67. Katz TM, Miller JH, Hebert AA. Insect repellents: historical perspectives and new developments. J Am Acad Dermatol 2008;58:865-71.
68. Fradin M, Day J. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002;347:13-18. (Pubitemid 34728952)